Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Lung; Disease, Fibroid (Chronic)
Interventions
DRUG

Ambulatory Oxygen

"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."

Trial Locations (1)

SW3 6NP

Royal Brompton Hospital, London

All Listed Sponsors
collaborator

Liverpool University Hospitals NHS Foundation Trust

OTHER_GOV

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Royal Brompton & Harefield NHS Foundation Trust

OTHER

NCT02286063 - Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) | Biotech Hunter | Biotech Hunter